1. [O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE. (1st July 2017) Authors: Budur, Kumar; West, Tim; Braunstein, Joel B.; Fogelman, Ilana; Bordelon, Yvette M.; Litvan, Irene; Roberson, Erik D.; Hu, Helen; Verghese, Philip B.; Bateman, Randall J.; Florian, Hana; Wang, Deli; Ryman, Davis; Gault, Laura; Goss, Sandra; Mendonca, Nuno; Rendenbach‐Mueller, Beatrice; Kerwin, Dia... Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 12 Page Start: P599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A three‐dimensional neuroimaging based deep learning model to predict Alzheimer's disease progression for clinical trial design. (31st December 2021) Authors: Gladstein, Scott; Yang, Liuqing; Wooten, Dustin W; Florian, Hana; Huang, Xin; Comley, Robert A.; Guo, Qi Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 1 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Baseline amyloid and tau PET imaging characteristics in the ongoing phase 2 study of tilavonemab in early Alzheimer's disease. (1st February 2022) Authors: Wooten, Dustin W.; Guo, Qi; Jin, Ziyi; Gladstein, Scott; Stage, Edwin; Hesterman, Jacob; Fisseha, Nahome; Florian, Hana; Comley, Robert A. Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 4 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Baseline amyloid and tau PET imaging characteristics in the ongoing phase 2 study of tilavonemab in early Alzheimer's disease. (December 2021) Authors: Wooten, Dustin W.; Guo, Qi; Jin, Ziyi; Gladstein, Scott; Stage, Edwin; Hesterman, Jacob; Fisseha, Nahome; Florian, Hana; Comley, Robert A. Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 4 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Identifying predictive factors of patient dropout in Alzheimer's disease clinical trials. (31st December 2021) Authors: Crimin, Kimberly; Allen, Patricia J; Abba, Iman; Ahlberg, Corinne; Benz, Luke; Lau, Hiuyan; Liu, Jingshu; Melhem, Fareed; Fisseha, Nahome; Florian, Hana Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY. (1st July 2006) Authors: Florian, Hana; Budur, Kumar; Wang, Deli; Robieson, Weining Z.; Soares, Holly; Braunstein, Joel B.; Holtzman, Dave M.; Bateman, Randall J.; Rendenbach-Mueller, Beatrice; Mendonca, Nuno Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 4 Page Start: P218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. O1‐05‐02: EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT‐126 AS A MONOTHERAPY TREATMENT IN MILD‐TO‐MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL. (1st July 2014) Authors: Othman, Ahmed; Meier, Andreas; Ritchie, Craig William; Florian, Hana; Gault, Laura M.; Tang, Qi Journal: Alzheimer's & dementia Issue: Volume 10:Supplement 4S(2014)Part 1 Page Start: P137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE. (1st July 2006) Authors: Soares, Holly; Feng, Sheng; Florian, Hana; Gold, Michael; Lon, Hoi-Kei; Mendonca, Nuno; Rendenbach-Mueller, Beatrice; Budur, Kumar Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7(2018)Part 19 Page Start: P1038 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P1‐050: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER'S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY. (1st July 2019) Authors: Florian, Hana; Arnold, Steven E.; Bateman, Randall; Braunstein, Joel B.; Budur, Kumar; Kerwin, Diana R.; Soares, Holly; Wang, Deli; Holtzman, David M. Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7(2019)Part 4 Page Start: P251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P4‐353: A PHASE 2 TRIAL OF THE EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT‐126 AS AN ADD‐ON TREATMENT IN MILD‐TO‐MODERATE ALZHEIMER'S DEMENTIA. (1st July 2014) Authors: Gault, Laura M.; Meier, Andreas; Florian, Hana; Gauthier, Serge; Lin, Yunzhi; Tang, Qi; Othman, Ahmed Journal: Alzheimer's & dementia Issue: Volume 10:Supplement 4S(2014)Part 16 Page Start: P917 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗